Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab ...

IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

An artificial intelligence-based image analysis model has more accurately predicted cancer biomarkers and outcomes compared with conventional methods.

The highest-paying dividend stocks in the Dow Jones Industrial Average right now are Verizon Communications (NYSE: VZ), ...

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...